NCCN Guidelines help clinicians determine what evaluations are appropriate, which treatment options are supported by current evidence, when additional testing may be important, and how care may change as a cancer changes.For patients, NCCN offers a version for patients.

KRAS care partner and advocate Chris Conneran joined an international discussion on how artificial intelligence is shaping cancer care, with a focus on patient trust and transparency.

By Terri Conneran, Founder, KRAS Kickers Reviewed for clinical accuracy by Salman R. Punekar, MD, MSc, Perlmutter Cancer Center at NYU Langone Health For this daraxonrasib lung cancer study, eligible RAS mutations were found at G12, G13, or Q61. The exact gene and exact mutation still matter because different RAS mutations can behave differently and may affect treatment or clinical trial options. For example, KRAS G12D, KRAS G12V, and KRAS G12C are all RAS mutations, but they